NewAmsterdam Pharma Co. NV

How big is NewAmsterdam Pharma Co. NV?

As of Jun 18, NewAmsterdam Pharma Co. NV has a market capitalization of 2,075.88 million, with net sales of 47.14 million and a net profit of -187.37 million over the last four quarters. Shareholder's funds are 757.50 million, and total assets are 864.62 million.

Market Cap: As of Jun 18, NewAmsterdam Pharma Co. NV has a market capitalization of 2,075.88 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 47.14 million and a net profit of -187.37 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 757.50 million, while total assets were reported at 864.62 million.

What does NewAmsterdam Pharma Co. NV do?

NewAmsterdam Pharma Co. NV is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $3 million and a net loss of $40 million as of March 2025. It has a market cap of approximately $2.08 billion and key metrics indicate it is currently loss-making with no dividend yield.

Overview:<BR>NewAmsterdam Pharma Co. NV operates in the Pharmaceuticals & Biotechnology industry and is classified as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 3 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -40 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 2,075.88 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.04 <BR>Return on Equity: -21.54% <BR>Price to Book: 2.67<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold NewAmsterdam Pharma Co. NV?

Is NewAmsterdam Pharma Co. NV overvalued or undervalued?

As of May 8, 2024, NewAmsterdam Pharma Co. NV is considered risky and overvalued due to negative earnings and poor return metrics, with a Price to Book Value of 2.91 and significantly negative EV to EBIT and EV to EBITDA ratios, while its stock has underperformed the S&P 500 with a year-to-date return of -29.14%.

As of 8 May 2024, the valuation grade for NewAmsterdam Pharma Co. NV has moved from does not qualify to risky, indicating increased concerns about its financial health. The company is currently considered overvalued, primarily due to its negative earnings and poor return metrics. The P/E ratio is not applicable as the company is loss-making, while its Price to Book Value stands at 2.91, and both the EV to EBIT and EV to EBITDA ratios are significantly negative at -7.70, highlighting the lack of profitability.<BR><BR>In comparison to peers, NewAmsterdam Pharma's valuation metrics are concerning. For instance, Ardelyx, Inc. has a P/E ratio of -15.85 and an EV to EBITDA of -21.07, also indicating risk, while Keros Therapeutics, Inc. is in a more favorable position with a P/E of 129.79 and an EV to EBITDA of 19.05, showcasing its strong performance relative to NewAmsterdam. The company's recent stock performance has lagged behind the S&P 500, with a year-to-date return of -29.14% compared to the index's 2.44%, reinforcing the view that NewAmsterdam Pharma is overvalued in its current state.

Is NewAmsterdam Pharma Co. NV technically bullish or bearish?

As of October 31, 2025, NewAmsterdam Pharma Co. NV's technical trend is mildly bullish, supported by bullish MACD and KST indicators, despite a bearish RSI, and it has significantly outperformed the S&P 500 with a year-to-date return of 42.14%.

As of 31 October 2025, the technical trend for NewAmsterdam Pharma Co. NV has changed from bullish to mildly bullish. The weekly MACD and KST indicators are bullish, while the RSI is bearish on both weekly and monthly time frames. The Bollinger Bands show a mildly bullish stance in both weekly and monthly periods. Daily moving averages indicate a bullish trend. Dow Theory and OBV show no trend on both weekly and monthly time frames. <BR><BR>The company has outperformed the S&P 500 significantly, with a year-to-date return of 42.14% compared to the S&P 500's 16.30%, and a one-year return of 104.99% versus 19.89% for the index. Overall, the current technical stance is mildly bullish, driven by the bullish MACD and KST, despite the bearish RSI.